Eswatini

Event
June 25, 2020

STAR EXHIBITION BOOTH

Check out our exhibition booth for more information about our STAR programs, webinars tackling HIVST in the context of COVID-19, various short films on HIVST and more! 

Resource
December 5, 2019

Hundreds of thousands of people continue to die from advanced HIV, also known as AIDS, because countries are still ill-equipped to detect and treat people suffering through advanced stages of the disease, according to a new report re

Resource
October 10, 2019
In this issue of the research Digest, we have assembled 86 abstracts published in July and August 2019 that feature evidence from Botswana (4), Burundi (1), Democratic Republic of Congo (1), Eswatini (3), Lesotho (4), Malawi (3), Mozambique (7), South Africa (51), Zambia (10) and Zimbabwe (9). Abstracts are grouped into linked categories to make browsing easier: Advocates (1); Health care providers (14); implementers and programmers (37); lay health workers (2); policymakers and government officials (1); and researchers (31).
News
August 12, 2019

Financial incentives to remain in school reduced HIV incidence among adolescent girls and young women in eSwatini (Swaziland) by 21%, and participants exposed to both financial incentives and a lottery open only to those who remained free of sexually transmitted infections (STIs) were 37% less li

Resource
July 30, 2019

mothers2mothers (m2m) is an African NGO working towards the Global Goals of ensuring good health for all and ending the AIDS epidemic by 2030.

Resource
July 16, 2019
Our 9th Research Digest assembles 87 abstracts published from May through June 2019 that feature evidence from Botswana (6), Eswatini/Swaziland (2), Malawi (12), Mozambique (4), South Africa (46), Tanzania (4), Zambia (7) and Zimbabwe (17).
Event
July 16, 2019

Have you been looking for an easier and more accurate way to quantify pediatric HIV treatment needs over time?

News
June 26, 2019
Results of a pivotal clinical trial among 7,829 women ages 16-35 in East and Southern Africa provide important evidence to help inform women’s choices for contraception and HIV prevention. The Evidence for Contraceptive Options and HIV Outcomes (ECHO) Study found no substantial difference in HIV risk among women using the three methods of contraception in the study – the copper-releasing intrauterine device (Cu-IUD), a levonorgestrel (LNG) implant (Jadelle) and depot medroxyprogesterone acetate-intramuscular (DMPA-IM), also known as Depo-Provera.
Resource
June 25, 2019
Injectable, intrauterine, and implantable contraceptives have been prioritised for programmatic delivery because of high contraceptive efficacy and safety. Robust evidence on the relative risks, particularly HIV susceptibility, and benefits of these contraceptive methods is important to inform women's decision making, provider counselling, and policy maker and regulatory decisions. Our primary objective was to compare HIV incidence among women using DMPA-IM, a copper IUD, or a levonorgestrel (LNG) implant.